• Explore /
  • Poster
  • / Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).

Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).

Abstract Poster

Authors

null

Walid Macaron

MD Anderson Cancer Center, Houston, TX

Walid Macaron , Hagop M. Kantarjian , Nicholas James Short , Farhad Ravandi , Nitin Jain , Tapan M. Kadia , Fadi Haddad , Yesid Alvarado Valero , Naval Guastad Daver , Gautam Borthakur , Courtney Denton Dinardo , Marina Konopleva , William G. Wierda , Jovitta Jacob , Edith Roy , Christopher Loiselle , Anna Milton , Juan Rivera , Rebecca Garris , Elias Jabbour

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01371630

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7011)

DOI

10.1200/JCO.2022.40.16_suppl.7011

Abstract #

7011

Poster Bd #

242

Abstract Disclosures

Similar Posters

First Author: Nicholas James Short

First Author: Shawn Patrick Griffin

First Author: Nicholas James Short

First Author: Abdul Hamid Bazarbachi